Recent Updates
Recently added Catalysts
ALLR Negative Sentiment Score: 25/100

Allarity Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. November 12, 2024 Deadline to file Lead Plaintiff Motion.

Key Takeaway: The Portnoy Law Firm has informed investors of Allarity Therapeutics, Inc. (ALLR) about a class action lawsuit concerning misleading statements made about the company's business practices during the period from May 17, 2022, to July 19, 2024. Allarity is facing scrutiny for the handling of the Dovitinib NDA and related conduct by former officers. Investors have until November 12, 2024, to file a lead plaintiff motion. The firm offers free consultations to help investors understand their options to recover potential losses.

Market Sentiment Analysis

CONCERNS & RISKS

  • Allarity is facing a class action lawsuit for misleading investors.
  • Investors were allegedly misled about the regulatory prospects of the Dovitinib NDA.
  • The company is under investigation for potential wrongdoing by former officers.
  • This situation could lead to significant legal, financial, and reputational damages.

Full Press Release Details

Investors can contact the law firm at no cost to learn more about recovering their losses
LOS ANGELES, Sept. 17, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ: ALLR) investors of a class action representing investors that bought securities between May 17, 2022, and July 19, 2024, inclusive (the "Class Period"). Allarity investors have until November 12, 2024 to file a lead plaintiff motion.
Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: lesley@portnoylaw.com, to discuss their legal rights, or click here to join the case. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.
The Complaint asserts that, throughout the Class Period, the Defendants issued materially false and misleading statements concerning the Company’s business practices, operations, and adherence to compliance policies. Specifically, it contends that the Defendants inflated the ongoing regulatory prospects of the Dovitinib NDA and engaged in illegal, illicit, or otherwise improper conduct related to the Dovitinib NDA and/or the Dovitinib-DRP PMA, involving Allarity and three of its former officers. This misconduct exposed the Company to heightened risks of regulatory and governmental scrutiny, enforcement actions, and significant legal, financial, and reputational damages. Following the disclosure that Allarity was under investigation for wrongdoing related to the Dovitinib NDA and/or Dovitinib-DRP PMA, the Company downplayed the likelihood of an enforcement action resulting from the investigation. As a result, the Company’s public statements were materially false and misleading throughout the relevant period.
Please visit our website to review more information and submit your transaction information.
The Portnoy Law Firm represents investors in pursuing claims against caused by corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.
Lesley F. Portnoy, Esq.
Admitted CA and NY Bar
Attorney Advertising

Tags

Frequently Asked Questions

How can Allarity Therapeutics investors recover losses?

Investors can contact the Portnoy Law Firm for a free case evaluation.

What is the deadline for filing a lead plaintiff motion?

Investors have until November 12, 2024, to file the motion.

What does the complaint against Allarity claim?

It claims defendants made false statements regarding business practices and compliance.

Who can I contact for more information?

Contact attorney Lesley F. Portnoy at 310-692-8883 or lesley@portnoylaw.com.

What were the effects of Allarity's alleged misconduct?

The misconduct led to risks of regulatory scrutiny and significant damages.

Last updated: Sep 17, 2024